LONDON, Oct. 6, 2004 (PRIMEZONE) -- Cancer drug development company Antisoma plc (LSE:ASM) will today present further promising data for its targeted apoptosis drug AS1406. Speaking at the Human Antibodies and Hybridoma meeting in Dublin, Antisoma's Chief Scientific Officer Dr Nigel Courtenay-Luck will reveal new data from the US National Cancer Institute showing that mice with advanced lymphomas live significantly longer when treated with AS1406 and that this effect is maintained even at doses tenfold lower than those previously tested.
Dr Courtenay-Luck said, "We've shown that AS1406 achieves powerful anti-cancer effects even at very low doses, underlining the potency of this agent and supporting our plans to take the product forward into clinical trials."
Except for the historical information presented, certain matters discussed in this statement are forward looking statements that are subject to a number of risks and uncertainties that could cause actual results to differ materially from results, performance or achievements expressed or implied by such statements. These risks and uncertainties may be associated with product discovery and development, including statements regarding the company's clinical development programmes, the expected timing of clinical trials and regulatory filings. Such statements are based on management's current expectations, but actual results may differ materially.
Notes for Editors:
About AS1406
AS1406 is one of three preclinical programmes being prioritised by Antisoma in addition to the three drugs the Company has in clinical trials. AS1406 has shown activity against both solid tumours and blood cancers in preclinical models. The drug has two components: an antibody, which allows it to bind to and get inside cancer cells, and the enzyme RNase, which then kills these cells. AS1406 has been developed under a CRADA (Collaborative Research and Development Agreement) with the United States National Cancer Institute.
About Antisoma
Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. The Company fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Antisoma forms partnerships with pharmaceutical companies to bring its products to market. In November 2002, Antisoma formed a broad strategic alliance with Roche to develop and commercialise products from Antisoma's pipeline. Please visit www.antisoma.com for further information about Antisoma.